Rare Diseases IE - Q1 2023

Rare Diseases

Q1 2023 | A promotional supplement distributed on behalf of Mediaplanet, which takes sole responsibility for its content

“Innovation is at the heart of achieving equity for people living with rare diseases.”

Vicky

McGrath, CEO, Rare Disease Ireland Page 05

www.healthnews.ie

“Globally, an estimated 400-475 million people live with a rare disease, most of whom will never be diagnosed.”

Cameron Fox, Health Innovation Lead, World Economic Forum Page

08

Our specialist services are helping to deliver the best therapy and support for children with cerebral palsy (CP).

Cerebral palsy refers to a group of non-progressive but often changing motor impairment syndromes secondary to lesions or anomalies of the brain arising in the early stages of development. The prevalence of CP in Ireland is approximately 2 per 1,000 live births, making it the most common cause of motor deficiency in young children.

The prevalence suggests there are at least 2,700 children with CP living in this country though the absence of a National CP register means that this population, and their needs, cannot be accurately determined.

A multidisciplinary approach

Following the implementation of Progressing Disabilities Services (PDS) nationwide, children with disabilities, such as CP, receive therapy locally with the support of clinicians with specialist knowledge and experience where required.

Central Remedial Clinic (CRC) National Specialist Services provide a full suite of Specialist Multidisciplinary Clinics including tone management, upper and lower limb orthopaedics, assistive technology and augmentative communication, specialist orthotics, specialised seating, feeding eating drinking swallowing (FEDS) and gait and movement analysis laboratory.

Our multidisciplinary approach means that children and families are seen by a full team of therapists and medical consultants who work together with the family to provide best-practice assessment and intervention.

Investment in education and training

Education and training form an important component of our national specialist services remit. Our staff provide virtual and in-person courses and talks both nationally and internationally. Research and evidence-based practice are a focus of our strategic plan and, in conjunction with academic partners in RCSI, the CRC successfully obtained three research grants in 2022 and we will begin recruitment for these important projects in 2023. Our services saw a 40% increase in referrals in 2022 and we are now looking to expand our team of therapists (physiotherapy, occupational therapy, speech and language therapy, dietetics, and psychology) in early 2023.

Our specialist services provide a supportive, dynamic and stimulating environment for therapists interested in working in the disability sector with a wealth of education, mentoring and support from our established multi-disciplinary teams.

Dr. Rory O’Sullivan PhD Head of Specialist Services, Research and Education, Central Remedial Clinic

Patient-led advocacy can lead to better rare disease policies

Broad patient advocacy fosters change that translates the newest research into practice and nurtures partnerships within the rare disease sector.

Yann Le Cam Chief Executive Officer, EURORDIS-Rare Diseases Europe

Meeting a policymaker and presenting a case for why they should take action is not only a form of direct patient advocacy. It is also a way to ensure policymakers see each rare disease patient as a person, rather than just another number.

Creating more informed rare disease policies

evidence-based decisions on legislation. They can improve regulatory policy and expedite the development of safe and effective drugs and provide them to patients who can benefit at the earliest moment. Well-informed decisions help clinicians and patients by unravelling the landscape of today’s healthcare and ensuring that rare disease patients are not left behind.

Julia Jenkins Executive Director,

Diseases

EURORDIS-Rare Diseases Europe has launched Brussels Rare Disease Week, February 6–9, during the leadup to Rare Disease Day. Its purpose is to strengthen advocacy knowledge and skills so that more rare disease patients and their families can effectively influence policies by sharing their stories and articulating their needs directly to policymakers. The engagement ensures a growing cohort of informed and actionoriented rare disease champions among policymakers themselves.

After the first virtual event two years ago, EURORDIS — with support from the Washington, DC-based EveryLife Foundation for Rare Diseases — gathered over 40 rare disease patient champions in Brussels for a weeklong learning and development experience. Throughout the week, the participants in Brussels had a chance to speak to representatives of the Swedish and Spanish EU Presidencies, the European Commission and Members of the European Parliament.

Rare disease policies that leave no patient behind

Proper patient advocacy helps policymakers make informed,

Patient advocacy has been a driving force in adopting policies that improve individual and community health.

People-centred policymaking is more effective

With the active involvement of the patient community in the development of milestone legislation — from the EU Regulation on Orphan Medicinal Products to the Paediatric Regulation, to the Directive on patients’ rights in cross-border healthcare — an integrated EU strategy on issues including diagnosis, treatment and care became a reality for the 30 million Europeans living with a rare disease.

These successes are never taken for granted by our community’s ceaselessly dedicated patient advocates. Far too many improvements in policymaking are desperately needed across Europe, so rare disease patient advocates are continuing their efforts to bring about policymaking that is more effective and, crucially, more people-centred.

Business Development Manager: Samantha Taylor Managing Director: Alex Williams Head of Ireland: Ross Bannatyne | Head of Print & Design: Thomas Kent Designer: Aimee Rayment

Project Manager: Robert Joyce robert.joyce@mediaplanet.com

Content Editor: Angelica Hackett O’Toole | Head of Digital Operations: Harvey O’Donnell Paid Media Manager: Jonni Asfaha

Social & Web Editor: Henry Phillips Digital Assistant: Carolina Galbraith Duarte All images supplied by Gettyimages, unless otherwise specified | Contact information: uk.info@mediaplanet.com or +44 (0) 203 642 0737

EveryLife Foundation for Rare

Providing children with cerebral palsy the highest level of intervention and care

Prof Aisling Ryan Consultant Neurologist at Cork University Hospital (CUH) and Adjunct Associate Professor, at Trinity College Dublin

An evolving story: improving care for hereditary ATTR amyloidosis

Hereditary ATTR amyloidosis, characterised by the abnormal build-up of amyloid protein in the body’s organs, is caused by an inherited mutation in the transthyretin (TTR) gene.

Hereditary transthyretin mediated amyloidosis (or hATTR amyloidosis) affects the nerves and heart, as well as the gastrointestinal and autonomic nervous systems. Over time, patients can lose motor function, become prone to falls and eventually develop heart failure.

Mutations of hATTR amyloidosis

“It is a tough, unpleasant disease as it progresses,” says Professor Aisling Ryan, Consultant Neurologist at Cork University Hospital. “Until recently, we didn’t have a treatment for it.”

There are over 120 different mutations in the TTR gene. In Ireland, the most common mutation is found in Donegal, while another recently-discovered mutation has been located in the Kerry and Cork area. Patients with this mutation often report carpal tunnel syndrome

in both hands and may have a personal or family history of heart problems.

Managing the symptoms

Cork University Hospital has a specialist diagnostic and treatment centre which helps patients manage symptoms.

“The availability of treatments has improved care in recent years” Professor Ryan adds. “There is solid evidence that these medicines have the potential to slow the progression or, for some patients, to improve lost function. If a health professional has even half a suspicion of amyloid, they should refer the patient to an expert.

“It’s an evolving story — and it’s been a privilege to be part of that journey.”

Recognising hereditary ATTR amyloidosis early can improve your quality of life

Genetic testing and screening are available for this serious, debilitating and sometimes fatal hereditary disease, hATTR amyloidosis.

Rosaline Callaghan, a retired Barrister living in Derry, learnt that she carried the gene mutation that causes hereditary ATTR amyloidosis, in 2007. At that time, she was told that finding a treatment for this fatal disease was unlikely.

“I saw my father die of this,” says Rosaline. “hATTR relentlessly affects your organs and nervous system.” Rosaline left work at 53 to travel, wanting to make the most of her time while she was in good health, having developed her own personal plan for the future, should the disease progress.

Early signs

While travelling in Turkey in 2018, she developed arm and wrist pain overnight. “I knew it was a sign,” she says. Later, she developed pins and needles and reduced feeling in her

Rosaline Callaghan Founder of

feet. She returned home to Derry, and following investigation, it was confirmed that she had hATTR amyloidosis

“My particular genetic mutation, T80A, originates from Northwest Donegal, so anyone genetically linked to that area should know about this — so should GPs and wrist surgeons, as Carpal Tunnel Syndrome can be an early sign,” she warns.

Get tested for hATTR

Now, Rosaline raises awareness of hATTR amyloidosis, alongside Amyloidosis Ireland and Rare Diseases Ireland.

She informs and urges people: “Today, treatment, genetic testing and family screening are available. If you suspect you may have hATTR amyloidosis, get tested now.”

Hereditary ATTR amyloidosis a rare disease with a unique Irish connection

Imagine a rare disease seen in a total of approximately 50,000 people across the world, with at least 120 known mutations. Then, imagine that the third most common mutation of this rare disease is believed to have originated from a 15-mile stretch of coastline right here in Ireland, in the extreme northwest of Donegal.

Mutation of the rare disease hATTR amyloidosis

From the tiny, remote area, this particular mutation, T80A, has spread across the world — as far as Australia in one direction and the USA in the other.

For those who are affected with the condition, the build-up of amyloid deposits in certain organs and systems, can lead to great difficulties in their function and, without treatment, can lead to organ failure and, often, death. The most common areas to be affected are the heart, the nervous system and the intestines.

Benefits of early hATTR amyloidosis diagnosis

In the last three to four years, a number of therapeutic options have been developed for the management and treatment of hATTR amyloidosis. Some treatments are now available in Ireland.

It is widely believed that early diagnosis has a significant effect on prognosis. Available treatments have been shown to slow down and, in some cases, halt the progression of the disease. Recognising the ‘red flags’ for the disease

in the early stage can improve outcomes for the patient. These early symptoms can be seen in the disease awareness website linked below.

How to encourage early diagnosis

There is a great drive to encourage those known to be carrying the mutation — or those who have had the diagnosis confirmed — to talk to their family members openly, share the signs and symptoms to look out for and encourage them to reach out for medical advice at the first sign of any symptoms. Family cascade screening widens the pool of people being tested for the genetic mutation and can lead to the earlier diagnosis of this disease.

Expanding treatments for hATTR amyloidosis

The last few years has seen a number of changes for patients with this disease and for their family members and carers. What was for many years described as a “rapidly progressive, debilitating, life-threatening, often fatal disease” now has treatment options which may slow down the progression and improve the patient’s quality of life.

The profound link of hATTR to Ireland serves as an example on Rare Disease Day why local Health Care Professionals need to remember to think rare/think genetic and how members of the public can be empowered by knowing the symptoms of an endemic disease.

Philippa Quigley Business Lead, Ireland, Alnylam

hATTR amyloidosis is a rare, hereditary condition caused by amyloid deposits from abnormal versions of a blood protein called transthyretin (TTR).

Alnylam are the sole sponsors of page three only. They nominated the two interviewees and reviewed all content prior to publication.

The most common areas to be affected are the heart, the nervous system and the intestines.

A global community demands visibility for people with a rare disease

People living with a rare condition experience a kind of invisibility which exacerbates inequity, discrimination and injustice. Imagine a community of over 300 million people fighting to be seen.

On Rare Disease Day 2023, Rare Diseases

Durhane Wong-Rieger President, RDI Council

International (RDI), a global network of rare disease organisations, has a simple call to action: that the world sees and recognises people living with a rare disease. With this goal in mind, on 28 February 2023, the network will host a virtual event organised in partnership with the Rare Disease Day campaign to spotlight rare disease groups around the world and help raise awareness among the public, policymakers and healthcare systems.

Recognition is a matter of life and death

In many countries, rare diseases are virtually invisible to healthcare systems and providers. Primary care clinicians are regularly unable to identify and effectively treat conditions to which they may have limited exposure. The result is a delayed diagnosis, misdiagnosis and inappropriate treatment or clinical management leading to disease progression with life-threatening consequences. The majority of rare diseases do not have an effective treatment as research into conditions that affect fewer people is not prioritised, and companies find financial incentives insufficient to drive the development of therapies. Where treatments are available, high pricing and unequal access mean that people fail to receive

Uniquely Anna

potentially lifesaving therapies and care. This is especially true for communities in low and middle-income countries.

Rare disease invisibility is social injustice

In the absence of disaggregated data, the social determinants of health — including work, gender, access to social services and education — are often left out of policies on rare diseases. For example, issues such as isolation and stigma, access to occupational opportunities and the heavy cost of rare diseases on families are often excluded from social support initiatives. Policymakers wrongly conclude that other frameworks, such as broader health and disability policies, sufficiently cover people living with a rare disease. However, rare conditions require specific attention, which focuses on the complexities presented by rarity.

A global shift for rare disease communities

There are positive signs that this previously unseen community is gaining visibility. As many countries do not have a definition of what constitutes a rare disease, RDI, working with the World Health Organization (WHO), has developed an international description of rare diseases to help inform policymakers worldwide.

IE/NP/0002

Patients and caregivers are people first, and rare disease is just one piece of their unique stories.

It’s our job to listen and learn from them to better understand their lives and help them have healthier futures.

In many countries, rare diseases are virtually invisible to healthcare systems and providers.

Hlawulani Mkhabela Strategic Engagement Manager, RDI

Celebrating rare disease day 2023 by shining a light on ‘rare’

Today, the last day of February, is Rare Disease Day; the day dedicated to raising awareness for the 300 million people around the world living with rare diseases.

Across the globe, the rare disease community is coming together to call for equitable access to social opportunity, treatment and care for people living with a rare disease and their families.

People affected

Vicky McGrath CEO, Rare Diseases Ireland

A rare disease is defined in Europe as a disease or disorder affecting less than 1 in 2,000 people. Although each condition is individually rare, collectively rare diseases affect a large number of people. One in 17 people live with a rare disease. Approximately 300,000 people are living with rare diseases in Ireland.

Rare diseases that we often hear about include childhood cancers, cystic fibrosis, epilepsy, meningococcal meningitis, PKU (phenylketonuria), sickle cell anaemia and spina bifida.

There are, however, more than 6,000 different rare diseases that we know of today, and 85% of these are considered ultra-rare, with each of the 5,100 ultra-rare conditions affecting less than 5 people in Ireland.

Stronger together

Rare Disease Day plays a critical part in building a rare disease community that is multi-disease, global and diverse — but united in its purpose. Since its launch in 2008, people living with rare diseases in Ireland have come together to mark Rare Disease Day.

Our purpose is equity. Equity in practice means meeting people’s specific needs and eliminating barriers preventing their full participation in society.

For people living with rare diseases, equity means social opportunity, non-discrimination in education and work — and equitable access to health, social care, diagnosis, treatment and research.

Innovation is at the heart of achieving equity for people living with rare diseases. Innovation is delivering genetics and genomics. Innovation is delivering cell and gene therapies. Innovation is delivering cures. But we need innovation to extend into everything that we do to support people living with a rare disease — healthcare delivery, approaches to education and employment practices.

Chain of lights

Today, the rare disease community in Ireland will join the global chain of lights. It serves as a symbolic way to break the isolation of living with a rare disease in Ireland; it raises awareness of rare diseases; and shines a light on our families, neighbours and friends that are living with rare diseases.

We invite everyone in Ireland to mark Rare Disease Day at 7 PM. Light up your home. Light up your business. Join us: show your colours, and celebrate rare.

New rare disease plan needed to improve Ireland’s rare disease pathways

Rare diseases collectively affect around 280,000 people in Ireland but the impact they have on patients, families and society is profound. Of the nearly 7,000 rare diseases, many are severe, chronic and progressive, with only 5% having an available treatment.

New national rare disease plan

Much has been achieved since Ireland’s ‘National Plan for Rare Diseases’ was published in 2014. The four-year government plan contained 44 recommendations focused on improving the diagnostic odyssey, identifying centres of excellence and establishing dedicated rare disease pathways.

Alexion, AstraZeneca Rare Disease recognises the progress made in

establishing the National Office for Rare Diseases, publication of a Model of Care for Rare Diseases and several Irish hospitals joining the European Reference Network. Despite this, an enormous amount of work remains. Along with the wider Irish rare disease community, Alexion is calling for the publication of a new national rare disease plan to support quicker diagnoses and better access to the most innovative treatments available.

Receiving an accurate diagnosis

One of the most significant challenges facing the rare disease community in Ireland is the length of time it can take to receive an accurate diagnosis. A recent survey from Rare Diseases Ireland reported that 37% of people living with a rare condition are waiting over five years

for a diagnosis, representing a lost opportunity to manage a disease as early as possible and achieve the best outcome for patients.1

It is hard to imagine waiting years to be diagnosed, only to be told your condition has no treatment option or it is unavailable where you live.

Ireland’s growing footprint

For more than 30 years, patients and families affected by rare disease have inspired us to find answers to the most complex scientific challenges by pushing the boundaries of medicine. Ireland is a country of growing significance for Alexion. In 2022, we announced further investment to increase our manufacturing capacity, thereby ensuring an uninterrupted supply of our drugs to an ever-increasing and diverse global patient population.

We are a committed partner to both the rare disease and pharmaceutical ecosystem in Ireland, with over 1,000 employees carrying out a range of different functions across two sites, aligned with our mission to make a difference for rare disease patients. We are equally committed to driving innovation in the rare disease space in Ireland and to working in partnership with the Irish Government to reduce the length of time it can take for a rare disease patient to receive an accurate diagnosis and access treatment.

References

1. Bowers, S. (2022) Many patients with rare diseases experience long waits for diagnoses, survey finds, The Irish Times, 31 January. Available at: https://www.irishtimes. com/news/health/ many-patients-with-rarediseases-experiencelong-waits-for-diagnosessurvey-finds-1.4789212 (Last accessed: 24 February 2023)

Date of preparation: February 2023

M/IE/UNB-U/0003

Innovation is at the heart of achieving equity for people living with rare diseases.

Shane Doyle SVP, Operations & Sustainability Alexion, AstraZeneca Rare Disease

Government and industry partnership is essential to deliver quicker diagnoses for rare disease patients and better access to innovative treatments.

Paid for by Alexion

Increasing recognition of ATTR cardiac amyloidosis can improve outcomes

Transthyretin Amyloidosis (ATTR) is a multisystemic condition, typically presenting with heart and/or neuropathy symptoms. It is being increasingly recognised in older people due to heightened awareness and advances in cardiac imaging techniques for diagnosis.

Amyloidosis is a general term used to describe a group of diseases where a particular protein ‘misfolds’ and subsequently accumulates into ‘amyloid fibrils’ which get deposited into various tissues and organs, interrupting their normal function and causing progressive disease.

Risk in older people

In ATTR amyloidosis, transthyretin — a normally occurring protein with important roles in the body — misfolds into fibrils as it exits the liver which deposit in the heart and nerves. It is subdivided into two types: genetic (which we call hereditary ATTR) or acquired (which we call wild-type ATTR). Wild-type ATTR typically affects older adults, presenting after the sixth decade of life and most commonly in those above 70 years. Because many of its initial manifestations can overlap with more common cardiac conditions such as high blood pressure, it has historically been underdiagnosed. Hereditary ATTR amyloidosis is caused by a genetic mutation in the TTR gene. While rare, there is a particular variant dominant in Ireland (‘T60A’ or ‘Donegal Amy’). However, over 120 mutations have been described across the world. Effective therapies have recently emerged for both genetic and wild-type subtypes.

Symptoms and signs

The heart and nervous system are the most frequently involved organs. Patients can present with heart failure syndrome or rhythm problems such as irregular heartbeat or slow heartbeat, which can lead to collapse or dizziness. In the nervous system, the ATTR amyloid fibrils can cause numbness and tingling.

Frequently, patients will have a history of carpal tunnel syndrome (trapped nerve-causing pins and needles) in both hands — often many years before their ATTR amyloidosis diagnosis. The ‘autonomic’ nervous system can also be affected. Low blood pressure, diarrhoea or constipation and erectile dysfunction can occur.

How is it diagnosed?

The initial suspicion of ATTR amyloidosis is typically based on an echocardiogram (heart ultrasound) and/or cardiac MRI scan.

A definitive diagnosis can then be made through a non-invasive pathway, using blood tests to outrule any blood cell abnormalities, followed by a special type of bone scan known in short-hand as a ‘DPD scan.’ In more complex cases, a biopsy-led diagnosis may be required.

ATTR-CM (transthyretin amyloid cardiomyopathy) is a rare, life-threatening condition that affects the heart and is associated with heart failure.

Photo posed by model. PP-UNP-IRL-0143

The heart and nervous system are the most frequently involved organs.

Professor Emer Joyce Consultant Cardiologist, Mater University Hospital

Dr Ross Murphy Consultant Cardiologist, St James’ Hospital

Gene-silencing drugs are among the innovative treatments for stiff heart

Cardiac amyloidosis is a long-described disorder where a waxy, protein-like substance is deposited on the heart muscle making it stiff and, ultimately, weak.

Cardiac amyloidosis can cause breathlessness (labelled as ‘heart failure’) and heart rhythm problems that can lead to death. It has two main types: one is driven by proteins made by the bone marrow and the other by proteins made in the liver.

Stiff heart syndrome

Both reproduce the same, stiff heart that looks overgrown or too thick on cardiac ultrasound. It can cause neuropathy when protein is deposited in nerves. This leads to tingling in the arms and legs and, sometimes, loss of control on bowel and bladder function.

The bone marrow variety is essentially a type of low-grade cancer requiring chemotherapy to control it. The liver-driven process is often a genetic disorder.

Available treatment

Until the last two years, there was little available treatment, apart from a liver transplant that can sometimes be done if caught early enough.

The liver version (TTR amyloid) can also occur in the elderly even if they don’t have the gene disorder or a family history of it.

Thankfully, there has been a sudden treatment breakthrough using a variety of novel technologies (including ‘gene-silencing’ drugs with possible long-term effects). Two new medications are now licenced in Ireland: a tablet-a-day and another involving intermittent infusion injections.

Helping families

We now have viable treatment to halt the deposition of these proteins. Large-scale clinical studies published years ago suggest that the earlier the patient receives treatment, the better the long-term outcome.

We must find affected families and pick up cases that are still early in development — to increase the amount of genetic testing and offer some hope for a disorder that, for so long, had no treatment.

Don’t live with the pain and discomfort: how to manage ATTR amyloidosis

John Wilson Amyloidosis Patient

It’s important to educate people about ATTR amyloidosis because the symptoms are not always obvious.

I’d never heard of amyloidosis until 2020 — I became unwell at work. I initially thought I was having a heart attack.

In August 2020, I met with my consultant who informed me of the diagnosis. To determine what type I had, I went through several blood tests, and this included genetic testing. We waited up to nearly 10 weeks for the genetic blood results which confirmed I had the hereditary type.

Watch out for symptoms

In November 2020, I was referred to Dr Emer Joyce, a cardiologist with a special interest in amyloidosis. I met with Dr Joyce who confirmed I had amyloidosis which was affecting my heart, joints and nerves. It was at this point we realised that I had symptoms for a lengthy period of time which included severe joint pain in hips, shoulder and feet, reduced feeling from the knees down, tiredness, weight loss and shortness of breath on occasion.

Understanding the symptoms of this condition is important. People may look at me and say “he looks great” when they have no idea that it took me 20 minutes to put my socks on this morning or that I had to stop what I was doing to catch my breath.

Better life with treatment

After several months of information-gathering, doctors visits and cocktails of tablets later, in May 2021, I was told that The National Amyloidosis Centre had advised I may be suitable for a drug trial taking place mid 2021 that involved gene editing. I went over in June for assessments to see whether I was a suitable candidate, and to our disbelief, I was. I went in for review every month, then visits became more spread out. My blood work was improved immensely, and the treatment improved my quality of life. I continue on medication for my heart and the neuropathy (pains). The symptoms vary at times and can be worse or better. I have improved feeling in my legs and feet now, too.

If you are a patient, family member or caregiver and in search of support, you can join the ATTR Amyloidosis All Ireland Support Group on Facebook, visit their website or send them an email, and an advocate will be in contact with you.

Patients’ Support Group

(Facebook) ATTR Amyloidosis

All Ireland Support Group

Website: amy.ie

Email: info@amy.ie

Large-scale clinical studies published years ago suggest that the earlier the patient receives treatment, the better the longterm outcome.

Rare diseases receive much less recognition and support than more common diseases, with patients and caregivers living with significant unmet health and social care needs.

Today, we are working towards better registration of rare diseases, using new genetic tests and artificial intelligence to improve diagnosis and care pathways, improving access to orphan drugs and developing new approaches to practically support patients and their families.

Supporting rare disease communities

Most of the rare disease research conducted in Northern Ireland (NI) is initiated and/or driven by families. I’m delighted our Raising Awareness of Rare Diseases Throughout All Communities (RARDTAC) team have been able to support so many projects that bring direct positive impacts to patients and the healthcare teams who support them.

This RARDTAC team has won impressive awards for their endeavours, often going above and beyond to deliver improvements on a very limited budget. Examples include introducing new laboratory tests to accelerate rare disease diagnosis, developing clinical decision support tools and providing an evidence base to help change clinical care practices.

However, there is still work to be done. Most actions in the NI rare disease plan 2022–23 were derived from our collaborative research, working in partnership with diverse stakeholders, including voices from people living with rare diseases at the forefront.

Rare disease research network

After many years in development, I am delighted to launch a funded cross-border research network with my colleague Dr Suja Somanadhan (University College Dublin), bringing hope to families living with rare disease(s) that collaborative efforts are raising awareness. This All-Ireland Rare Disease Interdisciplinary Research Network (RAiN) will strengthen effective links between researchers, industry, government, local authority, charity, patient and caregiver partners across Ireland.

As Director of postgraduate research for the School of Medicine, Dentistry and Biomedical Sciences at QUB, I’m acutely aware we need to train the next generation of doctors, nurses, biomedical scientists and researchers to continue driving forward progress for people living and working with rare diseases across Ireland.

Compelled by necessity, the rare disease community consists of pioneers developing creative and innovative health and social care

One-third of children with a rare disease die before their fifth birthday.

Changing the narrative for people living with a rare disease

Have you ever heard of Aarskog Syndrome?

How about Abetalipoproteinemia? Probably not. As with all rare diseases, they occur in less than 0.05% of the world population.

If we add up the total prevalence for all rare diseases, a very different picture emerges. Globally, an estimated 400-475 million people live with a rare disease, most of whom will never be diagnosed.

This lack of attention brings with it a range of unique challenges that deeply impact the lives of millions of patients across the world.

Unique challenges

For people living with rare diseases, the first hurdle is finding a proper diagnosis. There are over 7,000 rare diseases recognised, so the odds a doctor has seen a particular set of symptoms are slim.

Moreover, health data is often siloed, which can prevent medical professionals from accessing the information they need in time. Because of this, diagnoses take seven years on average in the United States and much longer in less developed nations.

More than 95% of rare diseases do not have an available treatment. Since an estimated 50-75% of rare diseases begin in childhood, this lack of treatment options is a key driver of mortality among children. In fact, one-third of children with a rare disease die before their fifth birthday.

Rare diseases put a huge burden on health systems – according to one estimate, rare disease treatment made up 10% of the UK’s NHS total spending in 2016. In addition, individuals living with rare diseases often face stigmatisation due to the public’s lack of understanding, and this marginalisation is a key driver of growing health inequities globally.

Positive advances

Collaborative research networks are improving data and resource sharing, and development of common standards and protocols is reducing the average time to a diagnosis. Advances in genomics and precision medicine are enabling researchers to better understand the underlying causes of many rare diseases and to develop targeted therapies.

Notable efforts are also being made when it comes to financing rare disease treatment.

Research on ‘orphan drugs’ — which would not be profitable to produce without government assistance — are now subsidised in jurisdictions including the US, EU and Japan. Work is also ongoing to understand how novel gene therapies can be delivered to people everywhere at affordable prices.

Patient advocates are increasingly making their voices heard, both as participants in clinical trials and as partners in the research process.

Improving our understanding and the way we support those living with rare diseases are crucial to countering health inequity and improving the lives of millions.

Cameron Fox Health Innovation Lead, Shaping the Future of Health and Healthcare, World Economic Forum

More than 95% of rare diseases do not have an available treatment.

Empowering rare disease communities and pioneers to strengthen research

Paid for by Queen’s University Belfast Find out more at qub.ac.uk/sites/RareDisease raredisease@qub.ac.uk

WRITTEN BY Professor Amy Jayne McKnight Professor of Molecular Epidemiology and Public Health, Director of Postgraduate Research, Rare Disease Research Lead, Co-Lead for RAiN, Centre for Public Health, Queen’s University Belfast